KZIA Kazia Therapeutics Ltd

Presentation to Annual General Meeting of Shareholders Dr James Garner Chief Executive Officer 8 November 2018

Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.

Kazia has delivered all milestones for 2018, with high-value data read-outs expected in 2019 GDC-0084 Glioblastoma Multiforme (GBM) Cantrixil Ovarian Cancer Preliminary data from phase 1 study in ovarian cancer Completion of Part A of phase 1 study (safety and dosing)* *Full publication plans to be determined ü Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 Receipt of Orphan Drug Designation from US FDA ü Start of phase 2a study in first-line GBM ü Commence potential collaborations in other brain cancers Data read-out from phase 2a study (safety and dosing) Data read-out from phase 2a study (preliminary efficacy) Data read-out from phase 1 study (preliminary efficacy) ü Commence other potential collaborations (TBC) ü

GDC-0084 Phase II Glioblastoma Multiforme

Orphan designation in February 2018 was an important validation for the GDC-0084 program Source: FDA; BIO; KL Miller (2017). Orphanet Journal of Rare Diseases. 12:114 FDA Orphan Designation recognises diseases affecting <200,000 Americans pa Orphan Designation provides benefits to companies throughout a drug’s lifecycle Waiver of PDUFA fees (application fees) at time of submitting an application for marketing authorisation Tax credits for qualified clinical research costs Up to seven years of additional market exclusivity, extending lifetime of product Potential access to orphan drug grants Orphan Designation is usually recognised by investors as value-driving Orphan designation is becoming more common for specialised novel drugs, particularly in areas such as oncology Drugs targeting rare diseases are more likely to be approved… …and small companies usually see a value inflection when Orphan Designation is granted Probability of Success (Phase I to Approval) 8.9% Average increase in company value with grant of orphan designation

The phase 2a study of GDC-0084 in glioblastoma is well underway, with the first cohort fully recruited Note: timelines are estimated and subject to periodic revision based on recruitment performance and treatment effect Step 1 Dose Optimisation Step 2 Expansion Cohort Step 3 Planned Registration Trial ‘Phase 2a’ Component March 2018 1H 2019 2H 2019 Dosing and safety data in newly-diagnosed population Preliminary efficacy signals and additional FDA-required data 6 – 24 patients 12 months 20 patients 6 months (potentially) 2023 Definitive data to support product approval by FDA

Current standard of care is essentially ineffective in approximately 65% of GBM cases Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). N Engl J Med 352:997-1003 Standard of Care (‘Stupp Regimen’) Debulking surgery where possible Radiotherapy + temozolomide Temozolomide maintenance therapy 6 weeks 4w 6 x 28-day cycles ~35% of patients respond to temozolomide Extends overall survival from 15 to 22 months ~65% of patients don’t respond to temozolomide Extends overall survival from 12 to 13 months GDC-0084 is being developed for the ~65% of newly-diagnosed GBM patients who will not respond to existing chemotherapy with temozolomide For these patients, there is no effective pharmacological treatment currently available

In phase 1, 7 / 27 patients (26%) showed a ‘metabolic partial response’ on FDG-PET Analysis courtesy of Professor Ben Ellingson, UCLA Brain Tumor Imaging Laboratory Pre-Dosing On GDC-0084 Pre-Dosing On GDC-0084

The PI3K class has been further validated with a third approved therapy, but GDC-0084 is unique FDA Approved July 2014 (blood cancers) [accelerated approval] FDA Approved September 2017 (blood cancers) [accelerated approval] FDA Approved October 2018 (blood cancers) [accelerated approval] In phase II human trials under US FDA oversight (brain cancer) ü ü ü Potentially fatal liver toxicity and diarrhoea Potentially fatal infections Potentially fatal infections and diarrhoea Appears generally safe and well-tolerated thus far Does not cross blood-brain barrier Does not cross blood-brain barrier Does not cross blood-brain barrier Does cross blood-brain barrier ü û û û ü û û û Zydelig (idelalisib) Aliqopa (copanlisib) Copiktra (duvelisib) GDC-0084

Recent data from Novartis at ESMO showed impressive results for PI3K inhibitor in breast cancer Source: Novartis company presentation Alpelisib (BYL719) is a PI3K inhibitor being developed for breast cancer Alpelisib only inhibits the alpha form of PI3K, and was not developed to cross the blood-brain barrier; GDC-0084 inhibits all four types of PI3K and was developed to cross the blood-brain barrier ESMO data showed increase in progression-free survival from 5.7 months to 11.0 months

There are now three ongoing human trials with GDC-0084, each in different forms of brain cancer Preclinical Phase I Phase II Phase III GDC-0084 PI3K / mTOR Inhibitor Licensed from Genentech in October 2016 Diffuse Intrinsic Pontine Glioma (DIPG) (collaboration with St Jude Children’s Research Hospital) Breast Cancer Brain Metastases (BCBM) (collaboration with Dana-Farber Cancer Institute) Glioblastoma Multiforme (GBM) (Kazia-sponsored) Potential future collaborations (to be determined)

Cantrixil Phase I Ovarian Cancer

Cantrixil has now progressed into Part B, and data is expected in calendar 2019 Part A: Dose Escalation 3 to 42 patients in up to 8 cohorts Seeks to establish maximum tolerated dose and understand safety profile Part B: Dose Expansion 12 patients, all at 5 mg/kg Seeks to provide potential efficacy signals ü 3 / 12 (25%) patients now enrolled Additional US site opening mid-November (Rhode Island, USA) Two patients from Part A still receiving treatment

Interim results from Part A of phase I study provide encouraging signals for potential safety and efficacy Complete Response CR Complete disappearance of target lesion on MRI / CT Partial Response PR At least 30% decrease in size of target lesion on MRI / CT Stable Disease SD Between 20% increase and 30% decrease in size of target lesion Progressive Disease PD At least 20% increase in size of target lesion on MRI / CT RECIST Criteria for early-phase oncology studies Study has progressed through most dose levels with only a single patient needed Suggests we will be able to give therapeutic doses with acceptable tolerability Three patients out of five (60%) have experienced ‘stable disease’ Suggests drug may have the potential to slow disease progression One patient has experienced a ‘partial response’ in combination with chemo Suggests possibility Cantrixil may be able to help reverse the course of ovarian cancer Key findings from June 2018 interim analysis 1 2 3

Part A has already shown evidence of activity with one partial responder to date Source: images courtesy of Professor Jim Coward, Icon Cancer Centre October 2017 (baseline) January 2018

Kazia is working closely with IQVIA on leading-edge data analytics to identify potential trial patients Site 004 HIGH ovarian cancer pts (30+) LOW drug use (>39 units) Site 003 HIGH ovarian cancer pts (30+) HIGH drug use (100+ units) Site 001 HIGH ovarian cancer pts (30+) LOW drug use (>39 units)

Company Summary

Kazia is running efficiently, with majority of funds applied directly to R&D Note: R&D – research and development; G&A – general and administrative Largely constant R&D investment… …against significant reduction in G&A costs Expenditure (AU$, millions) $11.1M $9.8M ò 12% Expenditure (AU$, millions) $8.5M $5.6M ò 34%

Kazia is now well-funded to see both programs through key data read-outs in calendar 2019 *NOX shares valued as at October 2018 $9.3M Current assets as at 30 June 2018 ~$3.5M* Shares in Noxopharm (ASX:NOX) $3.4M Proceeds (pre-costs) from institutional placement in Oct 18 Current funding allows:- Completion of phase IIa GDC-0084 trial Completion of phase I Cantrixil trial Working capital into calendar 2020 Multiple opportunities to engage with potential partners and licensees Obtained through IP settlement in Dec 2017 Placement to sector-specialist international investors in Oct 2018 Proceeds of Ongoing Share Purchase Plan

Other companies focused on the PI3K pathway have been highly-valued in the market Single asset company with one PI3K inhibitor in phase I human trials US$ 140 million Market Cap One PI3K inhibitor in phase II human trials, one other drug in phase III, and two in animal testing US$ 430 million Market Cap One PI3K inhibitor in phase II human trials Acquired by big pharma in 2011 for US$ 375 million One PI3K inhibitor approved in October 2018 for certain blood cancers, one other drug in human trials US$ 400 million Market Cap

Kazia has become a compelling investment proposition Lead program, GDC-0084, sourced from Genentech, the world’s most successful cancer drug developer Class of drugs, PI3K inhibitors, is well-validated and resurgent, but GDC-0084 is uniquely differentiated by ability to cross the blood-brain barrier Phase I data shows favourable safety profile and evidence of efficacy; phase II study underway under FDA oversight and with world-class centers of excellence in brain cancer High unmet need for new therapies, with only existing drug effective in just 35% of patients and no front-runner among drugs in development Collaborations progressing in childhood brain cancer and in brain cancer that has spread from elsewhere; largely funded by participating hospitals Second program, Cantrixil, in an ongoing phase I study with preliminary evidence of activity Four data read-outs from clinical trials over calendar 2019, with significant potential to drive financial value and potential partnering Company is well-funded to complete ongoing studies after institutional placement to sector-specialist investors 1 2 3 4 5 6 7 8